Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma

Clinical Trial ID NCT01397708

PubWeight™ 7.59‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01397708

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Intratumoral immunization: a new paradigm for cancer therapy. Clin Cancer Res 2014 1.24
2 Trial Watch: Immunostimulatory cytokines. Oncoimmunology 2012 1.19
3 Interleukin 12: still a promising candidate for tumor immunotherapy? Cancer Immunol Immunother 2014 1.17
4 Pathways and therapeutic targets in melanoma. Oncotarget 2014 1.17
5 New insights into IL-12-mediated tumor suppression. Cell Death Differ 2014 1.09
6 Immunological landscape and immunotherapy of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2015 1.06
7 Cellular unfolded protein response against viruses used in gene therapy. Front Microbiol 2014 0.83
Next 100